Human leukocyte migration inhibitory factor (LIF). II. Partial biochemical characterization of the substrate specificities for this lymphokine
- PMID: 322260
- DOI: 10.1111/j.1365-3083.1977.tb00328.x
Human leukocyte migration inhibitory factor (LIF). II. Partial biochemical characterization of the substrate specificities for this lymphokine
Abstract
Previously reported experiments suggested that an esterase or a protease, or both, might participate in the expression of human leukocyte migration inhibitory factor (LIF). To clarify this further, a wide variety of simple ester were tested for the ability to protect LIF against inactivation by the serine esterase inhibitor phenylmethylsulfonyl fluoride (PMSF). alpha-N-benzoyl-L-arginine ethylester (BAEE), a typical trypsin substrate, and bis-p-nitrophenyl phosphate (BNPP), a phosphodiester, were the only esters capable of retaining LIF activity in the presence of PMSF. Agents chemically closely related to these esters were inactive. Moreover, the protection afforded by BAEE and BNPP was the king that would be anticipated if the esters and irreversible inhibitor competed for the same site on LIF. Baee and BNPP also protected against inactivation by di-isopropylfluorophosphate (DFP), another irreversible serine esterase inhibitor. In addition, LIF-treated leukocytes partly escaped migration inhibition in the presence of BAEE and BNPP, respectively. These results indicate that human LIF contains a serine residue necessary for lymphokine activity. It is still not proved, however, that LIF as an enzyme is capable of hydrolyzing BAEE and BNPP, although it seems highly possible. The substrate specificities of a putative LIF enzyme are discussed on the basis of the chemical structure of BAEE and BNPP.
Similar articles
-
Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.Scand J Immunol. 1977;6(1-2):125-31. doi: 10.1111/j.1365-3083.1977.tb00327.x. Scand J Immunol. 1977. PMID: 322257
-
Human leukocyte migration inhibitory factor (LIF). IV. 3',5'-cGMP protects LIF against inactivation by the esterase inhibitor phenylmethylsulfonyl fluoride.Scand J Immunol. 1977;6(12):1357-61. Scand J Immunol. 1977. PMID: 203999
-
Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.Scand J Immunol. 1977;6(1-2):126-31. Scand J Immunol. 1977. PMID: 322258
-
Human leukocyte migration inhibitory factor (LIF) III. Further investigations on the serine protease nature of this lymphokine and its preference for arginine amides.Scand J Immunol. 1977;6(10):1055-62. Scand J Immunol. 1977. PMID: 335493
-
Substrate specificity of the human lymphokine leucocyte migration-inhibitory factor (LIF): radioenzymic assay and inhibition by cGMP.Scand J Immunol. 1979;10(1):61-7. doi: 10.1111/j.1365-3083.1979.tb01335.x. Scand J Immunol. 1979. PMID: 224450
Cited by
-
Studies on the active site of human leukocytic pyrogen.Inflammation. 1982 Mar;6(1):63-78. doi: 10.1007/BF00910720. Inflammation. 1982. PMID: 7085045
-
Production of leucocyte migration inhibitory factor (LIF) in infectious mononucleosis. Spontaneous release and lack of response to concanavalin A.Clin Exp Immunol. 1978 Jan;31(1):66-71. Clin Exp Immunol. 1978. PMID: 639351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous